ReNeuron Group welcomes Barbara Staehelin to its Board as Senior Independent Director

– UK, Bridgend –  ReNeuron Group plc (LON: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced the appointment of Barbara Staehelin to its Board as senior independent Non-Executive Director with immediate effect.

“I am delighted to welcome Barbara to the ReNeuron Board as a Non-Executive Director. She brings a wealth of market development experience in the medical services and biotech sectors and a strong track record in corporate governance. My colleagues and I look forward to working with her during this transformational time for ReNeuron.” said Board Chairman, Iain Ross.

About Barbara Staehelin

Her career in the international life sciences and technology sectors spans over 30 years and includes consulting CEO and Chair roles. She has led and co-founded four life science companies and is currently on the Board as President of the Audit and Risk Committee and a member of the Investment Committee at Assura Group, which operates in the health insurance sector and is headquartered in Switzerland. Her background is in biochemistry and until 2006, she was a member of the Global Executive Committee of Roche Diagnostics.

Ms. Staehelin holds a Director’s Certificate from Harvard University, the USA as well as executive education in new concepts for boards from University St. Gallen, Switzerland, health economy from the European School for Health Economics, France, and an MBA from INSEAD Fontainebleau, France.

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop ‘off the shelf’ stem cell treatments for diseases with significant unmet needs. The Company’s lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalized induced pluripotent stem cell platform to make allogeneic tissue cells of choice; in-house programs are currently focused on treatments for blood cancers and diabetes.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.